Table 1 Demographics. Demographics for all patients enrolled
Treatment Arm | |||
|---|---|---|---|
1 (n = 9) | 2 (n = 9) | Overall | |
Age (years) | |||
Median (range) | 75 (67–82) | 72 (66–85) | 74 (66–85) |
Race (n, %) | |||
White / Caucasian | 9 (100%) | 9 (100%) | 18 (100%) |
ECOG Performance Status (n, %) | |||
0 | 9 (100%) | 8 (89%) | 17 (94%) |
1 | 0 (0%) | 1 (11%) | 1 (6%) |
Gleason score (n, %) | |||
< 7 | 1 (11%) | 2 (22%) | 3 (17%) |
7 | 3 (33%) | 4 (44%) | 7 (39%) |
8 | 0 (0%) | 2 (22%) | 2 (11%) |
≥ 9 | 5 (56%) | 0 (0%) | 5 (28%) |
Unknown | 0 (0%) | 1 (11%) | 1 (6%) |
Metastatic sites (n, %) | |||
Visceral | 2 (22%) | 0 (0%) | 2 (11%) |
Bone | 2 (22%) | 5 (56%) | 7 (39%) |
Distant lymph nodes | 6 (67%) | 4 (44%) | 10 (56%) |
Baseline PSA (ng/mL) | |||
Median (range) | 32.6 (4.17–1090) | 11.2 (2.09–68.4) | 16.25 (2.09–1090), |
Baseline PSA doubling time (months) | |||
Median (range) | 2.8 (1.4–63.9) | 2.2 (1.0–25.8) | 2.55 (1.0–63.) |